Free Trial

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$11.84 -0.09 (-0.71%)
As of 01:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$11.69
$12.01
50-Day Range
$8.71
$15.66
52-Week Range
$7.80
$28.09
Volume
66,450 shs
Average Volume
637,691 shs
Market Capitalization
$646.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.86
Consensus Rating
Buy

Company Overview

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

BCAX MarketRank™: 

Bicara Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 646th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bicara Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bicara Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for BCAX.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BCAX.
  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
BCAX Bicara Therapeutics Inc.
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the beginning of the year. Since then, BCAX shares have decreased by 31.5% and is now trading at $11.93.

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.28.

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Top institutional investors of Bicara Therapeutics include Atle Fund Management AB (0.27%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/13/2025
Today
7/25/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$8.00
Potential Upside/Downside
+169.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
24.62
Quick Ratio
24.62

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.04 per share
Price / Book
1.31

Miscellaneous

Outstanding Shares
54,540,000
Free Float
46,083,000
Market Cap
$646.03 million
Optionable
N/A
Beta
N/A
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners